Alivio Therapeutics

Alivio Therapeutics is a pioneering player in the realm of precision immunomodulation, aiming to combat chronic and acute inflammatory disorders at their source. The company's unique approach involves targeting disease immunomodulation, focusing on adjusting the immune system at the specific site of the disease while minimizing impact on the rest of the immune system. This novel strategy holds the potential to effectively address numerous challenging chronic and acute inflammatory disorders. Alivio Therapeutics holds exclusive rights to an innovative inflammation-targeting technology, derived from the research of Dr. Karp (BWH/HMS) and Dr. Robert Langer (MIT). This groundbreaking technology has consistently demonstrated the ability to direct immunomodulatory compounds to inflamed tissue, notably enhancing treatment efficacy and reducing systemic side effects. Validated in multiple labs and preclinical models, the technology exhibits promise in addressing inflammation in various bodily areas, including the GI system, bladder, joints, and skin. The platform is adaptable for use with a range of medications, spanning small molecules, biologics, and nucleic acids, either alone or in combination, and is tailored for oral or alternative methods of administration. Leveraging this technology, Alivio aims to effectively tackle various conditions where inflammation plays a pivotal role, yet targeted and efficacious treatments are presently limited. Founded in 2016, Alivio Therapeutics operates in the Biotechnology and Health Care industries. The company's most recent investment amounts to $3.30 million, a grant investment received on 12 September 2018 from the U.S. Department of Defense.